Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 mRNA levels of seven selected genes in 97 estrogen receptor alpha-positive breast tumors

From: Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma

  mRNA levels Expression status
Gene Mean ± SD Median Range Underexpresseda Normal Overexpressedb
CYP2A6 344.0c ± 1540.6 0.9 0.001–9741.1 15 (15.5)d 58 (59.8)d 24 (24.7)d
CYP2B6 103.3 ± 172.7 37.0 0.03–1053.1 1 (1.0) 22 (22.7) 74 (76.3)
FMO5 5.2 ± 6.3 2.6 0.10–30.1 1 (1.0) 43 (44.3) 53 (54.7)
GSTM3 3.1 ± 3.5 2.0 0.07–21.2 2 (2.1) 60 (61.8) 35 (36.1)
SULT2B1 7.5 ± 10.5 4.5 0.17–84.4 0 61 (62.9) 36 (37.1)
NAT1 46.5 ± 55.4 21.5 1.1–295.6 0 20 (20.6) 77 (79.4)
ABCC11 37.1 ± 60.4 15.9 0.04–461.7 3 (3.1) 27 (27.8) 67 (69.1)
  1. a Less than mean values for the normal breast Ntarget minus two standard deviations (SDs) (or Ntarget value = 0.1 when the latter calculation gave a negative value). b Greater than mean values for the normal breast Ntarget plus five SDs. c The n-fold differences in target gene expression relative to the TATA box-binding protein (TBP) gene and the normal breast tissues. d Number of patients (percentage).